PubMed Health⌕ Search

Biomedical subjects

W Mattsson

Publications and source records attributed to W Mattsson.

At least 19 recordsLinked to original sources
PubMed1984

Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.

A phase II study of 4'-epi-doxorubicin in 39 fully evaluable patients with advanced postmenopausal breast cancer has been performed. The patients received 20 mg of 4'-epi-doxorubicin iv weekly, irrespective of surface area. This dose schedule follows previous work with doxorubicin, showing good therapeutic effect with very low toxicity. The preliminary results of this study of 4'-epi-doxorubicin confirm that the drug is very active in breast cancer (51% objective response rate) and that the low-dose weekly approach is well-accepted with remarkably low toxicity (59% of patients had no complaints of toxic effects).

Adult↗
PubMed1983

A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.

Prednimustine is an ester of chlorambucil and prednisolone. The drug has had some activity in experimental as well as in human tumors, including breast cancer. The objective of the current study is to compare the clinical effectiveness and toxicity of prednimustine with its components of chlorambucil plus prednisolone, and to compare the clinical effectiveness and toxicity of a continuous treatment with an intermittent one. Two hundred and one patients with advanced breast cancer were randomized to the following treatments: I: prednimustine continuously; 40 mg/m2 d; II: prednimustine intermittently, 160 mg/m2 d 1 to 5, repeated every three weeks; and III: chlorambucil 8 mg/m2 d plus prednisolone 8 mg/m2 d, both given continuously. All treatments were given orally. One hundred and ninety five patients were evaluable for assessment of response to the treatments. The response rates were 21% in both of the prednimustine-treated groups, whereas only 11% of the patients treated with chlorambucil and prednisolone responded. The duration of remission with continuous prednimustine was longer than with the other two treatment groups, but not significantly so. One hundred and ninety five patients were evaluable for assessment of hematologic toxicity. No differences were observed between the two prednimustine-treated groups, whereas the group treated with chlorambucil plus prednisolone experienced a significantly higher degree of leukopenia and/or thrombopenia. Subjective toxicities, nausea, vomiting and psychical symptoms were only moderate in the three treatment groups, but significantly more pronounced in the group treated with intermittent prednimustine. Because of these promising results, prednimustine should be compared to other alkylating agents in patients with advanced breast cancer in randomized trials.

Adult↗
PubMed1983

Bleomycin-mitomycin C in advanced carcinoma of the cervix. A third look.

Thirty-three patients with advanced cervical cancer (31 squamous cancer, two adenosquamous cancer) previously untreated with cytotoxic drugs, were treated with bleomycin, 5 mg daily, for seven days and mitomycin C, 10 mg, on day 8. This regimen was repeated four times at two-week intervals. All but one patient had previously been treated with radiotherapy; 36% of the patients had an objective response (five complete remission (CR), median duration 12 months; seven partial remission (PR), median duration six months). Severe myelosuppression occurred in nine patients. One drug-related death due to thrombocytopenia occurred. Three patients developed pulmonary fibrosis and one of them died of respiratory failure. The bleomycin-mitomycin C regimen has a definite but clearly limited effect in advanced cancer of the uterine cervix.

Adult↗
PubMed1983

Current status of high dose progestin treatment in advanced breast cancer.

Progestins, especially high dose medroxyprogesterone acetate, are receiving renewed attention in treatment of advanced breast cancer. The trials reviewed here indicate that such regimens may be as effective as tamoxifen in postmenopausal unselected cases, and that they may be effective as second-line treatment in patients resistant to tamoxifen and/or to cytotoxic chemotherapy.

Administration, Oral↗
PubMed1982

A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer.

In a Phase II study, 50 patients with advanced breast cancer were treated with a combination of 5-fluorouracil (1000 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination chemotherapy and 40 patients had received endocrine treatment, objective responses were obtained in 29 patients (six complete, 23 partial). The survival was significantly correlated to the response (P less than 0.001, log rank test) complete versus partial response, partial response versus no change, no change versus progressive disease. The regimen was well tolerated (19 of 50 experienced nausea). Thirteen patients had hematopoietic toxicity at the day of starting a new course and in six cases, the FuMi regimen had to be discontinued because of longlasting thrombocytopenia. Otherwise, no side-effect of clinical importance was observed. The FuMi regimen is now compared with Adriamycin regimens and can be recommended for both first line chemotherapy and salvage chemotherapy.

Adult↗
PubMed1982

Vincristine, Adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung.

Twelve patients with small-cell anaplastic carcinoma of the lung were treated with vincristine 1 mg/m2 i.v. day 1, adriamycin 50 mg/M2 i.v. day 1, cyclophosphamide 1,000 mg/m2 i.v. day 1, and etoposide 80 mg/m2 i.v. day 2, 4, 6 given on an outpatient basis and repeated at 3-week intervals. As consolidation therapy seven patients received two courses of BCNU median 29 mg/m2 (range 24-73 mg/m2) short term intraarterial infusion in the bronchial artery with 2 to 3-weeks intervals. One patient with limited disease had no evidence of disease for 13+ months and one patient complete remission for 3+ months. Four of ten patients with extensive disease had complete remission for median 5 months (range 2+ to 5+ months) and four patients had partial remission for median 5 months (range 4 to 5+ months). Despite side effects the chemotherapy was well tolerated by the patients. The results correspond to those obtained with other effective regimens in small-cell anaplastic carcinoma of the lung.

Adult↗
PubMed1982

Remission by chemotherapy of the Eaton-Lambert myasthenic syndrome in a patient with small cell bronchogenic carcinoma.

A 70-year-old man developed symptoms compatible with the Eaton-Lambert syndrome, and a small cell bronchogenic carcinoma was diagnosed. During treatment with cytostatics his muscular strength was restored and the lung tumour as well as the electrophysiologic findings characteristic of the Eaton-Lambert syndrome disappeared. To our knowledge, it has not been reported before that chemotherapy alone of a small cell bronchogenic carcinoma has resulted in clinical, roentgenologic, and electrophysiologic remission of the Eaton-Lambert syndrome.

Adenocarcinoma, Bronchiolo-Alveolar↗
PubMed1982

A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer.

A phase II study of weekly low-dose doxorubicin (6 to 12 mg/m2) showed it to be an effective, well-tolerated therapy in advanced breast cancer. Although most of the 34 patients studied had been clinically resistant to previous endocrine measures and/or other kinds of chemotherapy, had a median score of 60 on Karnofsky's index, and had predominantly visceral metastases, an objective response was obtained in 20 of 34 patients (four complete remissions, 16 partial remissions) for a median duration of 12+ months. Ten patients experienced no change in their condition for three to 12 months (median, six months). Eight of the 17 patients who had myelosuppression at the beginning of the study had an objective response lasting 4+ to 27+ months (median, 11 months). Eleven of the patients had previously received 500 or more mg/m2 of doxorubicin and were retreated with additional doses of doxorubicin (median cumulative dose, 800 mg/m2) without any clinical signs of toxicity.

Adult↗
PubMed1981

Toxic epidermal injury following intraarterial adriamycin treatment.

Toxic epidermal injury was induced in the right forearm and thumb of a 74-year-old woman following two courses of 28 mg/m2 Adriamycin infused in the brachial artery with a three-week interval. The toxic epidermal injury was treated with a wet dressing solution and a neomycin cream without corticoids; it healed in one month. Afterwards the woman received 22 courses of Adriamycin intravenously or intraarterially in 5.5 or 11 mg/m2 doses, but the toxic epidermal injury did not occur.

Brachial Artery↗
PubMed1980

Mitomycin C in advanced gallbladder carcinoma.

Seven patients with advanced gallbladder carcinoma were given intraarterial infusions of 10 to 15 mg mitomycin C with 10 to 24 days' interval, 3 received intravenous infusion (10 mg/m2) with median 3 weeks' interval. Stationary disease was obtained in 4 patients, progressive disease in 4, and treatment failures in 2. The median survival after mitomycin C treatment was 4 months (range 1-23 +). Irreversible thrombocytopenia occurred in 2 patients and a severe gastrointestinal bleeding episode in one.

Aged↗
PubMed1980

Short-term intra-arterial mitomycin C in hepatic metastases.

Short-term intra-arterial Mitomycin C treatment of hepatic metastases from various malignancies was performed in 24 evaluable patients. An objective regression was obtained in 12 patients. The median survival of responders was 11 months compared with 3 months in nonresponders. No complication of the technical procedure occurred and the treatment was well tolerated. The only side effect of clinical importance was thrombocytopenia, which occurred at a median dose of 45 mg of Mitomycin C.

Adult↗
PubMed1980

Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: a third look.

Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate. All patients had previously been treated with external irradiation and 2 intracavitary radium applications. The median recurrence-free interval was 22 months. All patients were evaluable. Five patients (21%) had partial remission for a median duration of 5 months (2 to 9 months), and 7 patients had static disease. When used in dosages that do not precipitate dangerous toxicity this therapy is not effective and in the authors' opinion should be abandoned.

Adult↗
PubMed1979

Chemotherapy of advanced transitional cell carcinoma of the renal pelvis: report of 3 cases treated with vinblastine and chloroethyl-cyclohexyl-nitrosourea.

Three patients with advanced transitional cell carcinoma of the renal pelvis were treated with 5 mg./m.2 body surface vinblastine intravenously weekly and 130 mg./m.2 chloroethyl-cyclohexyl-nitrosourea orally with 6-week intervals. One patient had a partial remission for 1.5 months and 2 had stationary disease for 6 and 2 months.

Carcinoma, Transitional Cell↗
PubMed1979

Intra-arterial chemotherapy of malignant head and neck tumours with superselective angiographic technique.

A technique is described for repeated superselective angiographic infusion of anticancer drugs into advanced malignant tumours of the head and neck region. The technique allows for a high concentration of the drug in the tumour and, furthermore, it is possible to ensure that the infused anticancer drug adequately reaches the tumour. Mitomycin C was given to 15 patients with advanced malignant tumours of the head and neck region. In 16 patients a partial remission was seen, and in another 5 patients a subjective improvement was reported. No complications were observed.

Adult↗